NasdaqGS - Nasdaq Real Time Price USD

DexCom, Inc. (DXCM)

124.34

-13.67

(-9.91%)

At close: April 26 at 4:00 PM EDT

124.38

+0.04

(+0.03%)

After hours: April 26 at 7:54 PM EDT

Dexcom Reports First Quarter 2024 Financial Results

SAN DIEGO, April 25, 2024--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.

Business Wire yesterday
Dexcom Publishes Annual Sustainability Report

SAN DIEGO, April 03, 2024--DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy.

Business Wire 24 days ago
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

SAN DIEGO, April 02, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be

Business Wire 25 days ago
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

SAN DIEGO, March 05, 2024--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription. There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology. Today, Dexcom G7 is available for them with a prescripti

Business Wire last month
Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

EDINBURGH, Scotland, March 05, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom continuous glucose monitoring (CGM) for automated insulin delivery (AID) systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association b

Business Wire last month
Dexcom Announces Upcoming Conference Presentation

SAN DIEGO, February 27, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th.

Business Wire last month
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

SAN DIEGO, February 08, 2024--Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Business Wire 2 months ago
Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

EDINBURGH, Scotland & SAN DIEGO, February 06, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of their latest CGM system, Dexcom ONE+. The system is available today in Spain, Belgium, and Poland and launches next week in the Netherlands. In some countries Dexcom ONE+ replaces the previous generation Dexcom ONE sensor. Dexcom ONE+ uses Dexcom’s best-in-class and most accurate sensor design. De

Business Wire 2 months ago
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time

SAN DIEGO, January 23, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations websi

Business Wire 3 months ago
Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland

GALWAY, Ireland, January 19, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, has officially broken ground on its new state-of-the-art manufacturing facility, located in Athenry, Co. Galway. This marks the first step in the realisation of this facility, which will bring more than 1,000 jobs to the area and represents one of the biggest single private sector investments ever in the West of Ireland.

Business Wire 3 months ago
A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2

EDINBURGH, Scotland, January 15, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa. The announcement comes just a month after the system launched in the United States and combines the power and accuracy of Dexcom G7 with the discretion of t

Business Wire 3 months ago
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook

SAN DIEGO, January 08, 2024--Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook

Business Wire 3 months ago
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, December 19, 2023--DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024.

Business Wire 4 months ago
Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump

SAN DIEGO, December 06, 2023--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world’s most accurate1,2 CGM system.

Business Wire 4 months ago
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day

SAN DIEGO & EDINBURGH, Scotland, November 14, 2023--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) systems for people with diabetes, is teaming up with Dexcom Warriors from around the globe to help raise awareness for the need to improve access to life-changing diabetes technology during National Diabetes Awareness Month in the U.S. and Canada (November) and on World Diabetes Day (November 14).

Business Wire 5 months ago
Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2

LONDON, November 08, 2023--Dexcom has announced new market research following the new Technology Appraisal from NICE for hybrid closed loop systems.

Business Wire 5 months ago
Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program

SAN DIEGO, October 26, 2023--Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program

Business Wire 5 months ago
Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada

BURNABY, British Columbia, October 05, 2023--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be available on October 10, 2023, for Canadians living with all types of diabetes ages two and older, including those who are pregnant. Its introduction brings the most accurate CGM on the market*,1 to Canadians, offering users a new

Business Wire 6 months ago
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD

SAN DIEGO, October 02, 2023--Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

Business Wire 6 months ago
Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.

SAN DIEGO, September 29, 2023--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023. Management will hold a conference call to review the company's third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and w

Business Wire 6 months ago

Performance Overview

Return	DXCM	S&P 500
YTD	+0.20%	+6.92%
1-Year	+0.31%	+25.26%
3-Year	+19.85%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

DexCom, Inc. (DXCM)

Dexcom Reports First Quarter 2024 Financial Results

Dexcom Publishes Annual Sustainability Report

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Dexcom Announces Upcoming Conference Presentation

Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time

Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland

A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook

Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump

Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day

Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2

Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program

Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD

Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.

Performance Overview